Claire N Harrison

List of Publications by Year
in descending order

181	13,756	36303 51	22166 113
papers	citations	h-index	g-index

185	185	185	8160
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Annals of Hematology, 2022, 101, 131-137.	1.8	20
2	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	4.5	32
3	A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol. PLoS ONE, 2022, 17, e0263195.	2.5	1
4	A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study. Therapeutic Advances in Hematology, 2022, 13, 204062072210844.	2.5	2
5	How I manage myeloproliferative neoplasmâ€unclassifiable: Practical approaches for 2022 and beyond. British Journal of Haematology, 2022, , .	2.5	2
6	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Journal of Clinical Oncology, 2022, 40, 1671-1680.	1.6	60
7	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	4.6	46
8	A randomised comparison of <scp>FLAGâ€ida</scp> versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the <scp>UK NCRI AML17</scp> trial. British Journal of Haematology, 2022, , .	2.5	0
9	Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice. Current Research in Translational Medicine, 2022, 70, 103338.	1.8	1
10	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinaseâ€2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology, 2022, 198, 317-327.	2.5	18
11	Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology, 2022, 18, 2393-2402.	2.4	14
12	Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematology,the, 2022, 9, e434-e444.	4.6	18
13	Abstract LB108: Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. Cancer Research, 2022, 82, LB108-LB108.	0.9	1
14	<scp>Chronic myeloid leukaemia</scp> patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted Tâ€cell phenotype. British Journal of Haematology, 2022, 198, 1011-1015.	2.5	7
15	Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. British Journal of Haematology, 2021, 193, 150-154.	2.5	10
16	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia, 2021, 35, 485-493.	7.2	70
17	Clinicopathological characterisation of myeloproliferative neoplasmâ€unclassifiable (MPNâ€U): a retrospective analysis from a large UK tertiary referral centre. British Journal of Haematology, 2021, 193, 792-797.	2.5	9
18	Evidence of robust memory Tâ€cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2). British Journal of Haematology, 2021, 193, 692-696.	2.5	13

#	Article	IF	Citations
19	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HemaSphere, 2021, 5, e553.	2.7	7
20	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 2021, 17, 1449-1458.	2.4	31
21	ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. ELife, 2021, 10, .	6.0	11
22	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia, 2021, 35, 2989-2993.	7.2	34
23	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia, 2021, 35, 3573-3577.	7.2	41
24	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2) induces neutralising antibody and polyfunctional Tâ€cell responses in patients with chronic myeloid leukaemia. British Journal of Haematology, 2021, 194, 999-1006.	2.5	55
25	Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021. HemaSphere, 2021, 5, e609.	2.7	1
26	Updated results of the placeboâ€controlled, phase III JAKARTA trial of fedratinib in patients with intermediateâ€2 or highâ€risk myelofibrosis. British Journal of Haematology, 2021, 195, 244-248.	2.5	37
27	Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms. Genome Research, 2021, 31, 1381-1394.	5.5	3
28	Current and future status of JAK inhibitors. Lancet, The, 2021, 398, 803-816.	13.7	117
29	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematology,the, 2021, 8, e658-e665.	4.6	17
30	Realâ€world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. British Journal of Haematology, 2021, 192, 62-74.	2.5	18
31	Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies. Blood, 2021, 138, 1505-1505.	1.4	5
32	Immune Checkpoint Analysis of T Effectors and Regulatory T Cells in Patients with CML Reveals Increased Expression at Diagnosis and with Refractory Disease. Blood, 2021, 138, 2545-2545.	1.4	0
33	A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). Blood, 2021, 138, 3643-3643.	1.4	7
34	Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly. Blood, 2021, 138, 2576-2576.	1.4	0
35	Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial. Blood, 2021, 138, 389-389.	1.4	9
36	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	4.1	53

#	Article	IF	Citations
37	Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition. Cancer Medicine, 2020, 9, 8301-8309.	2.8	12
38	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	5.2	7
39	Current and future therapies for myelofibrosis. Blood Reviews, 2020, 42, 100715.	5.7	12
40	How we manage Philadelphiaâ€negative myeloproliferative neoplasms in pregnancy. British Journal of Haematology, 2020, 189, 625-634.	2.5	33
41	Management of myelofibrosis after ruxolitinib failure. Annals of Hematology, 2020, 99, 1177-1191.	1.8	62
42	Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms. British Journal of Haematology, 2020, 191, 21-36.	2.5	3
43	Current and future role of fedratinib in the treatment of myelofibrosis. Future Oncology, 2020, 16, 175-186.	2.4	10
44	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure. American Journal of Hematology, 2020, 95, 594-603.	4.1	96
45	A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK. British Journal of Haematology, 2020, 188, e105-e109.	2.5	1
46	Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasmâ€associated venous thromboembolism in a large tertiary centre in the UK. British Journal of Haematology, 2020, 189, e79-e81.	2.5	24
47	Bone marrow niche dysregulation in myeloproliferative neoplasms. Haematologica, 2020, 105, 1189-1200.	3.5	20
48	The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. Blood, 2020, 136, 49-50.	1.4	21
49	Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial. Blood, 2020, 136, 10-12.	1.4	2
50	Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]. Blood, 2020, 136, 2-3.	1.4	9
51	The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells. Blood, 2020, 136, 37-38.	1.4	2
52	Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval. Blood, 2020, 136, 46-47.	1.4	6
53	MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients. Blood, 2020, 136, 43-43.	1.4	17
54	A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. Blood, 2020, 136, 43-44.	1.4	0

#	Article	IF	Citations
55	Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica, 2019, 104, 1580-1588.	3.5	42
56	Facing erythrocytosis: Results of an international physician survey. American Journal of Hematology, 2019, 94, E225-E227.	4.1	10
57	Essential thrombocythaemia treated with recombinant interferon: â€˜real world' United Kingdom referral centre experience. British Journal of Haematology, 2019, 186, 561-564.	2.5	6
58	<scp>UK</scp> results from the myeloproliferative neoplasms (<scp>MPN</scp>) landmark survey on the symptom, emotional and economic burden of <scp>MPN</scp>. British Journal of Haematology, 2019, 186, e1-e4.	2.5	6
59	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica, 2019, 104, 659-668.	3.5	56
60	Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms. Haematologica, 2019, 104, 639-641.	3.5	7
61	The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. Blood, 2019, 134, 2107-2111.	1.4	12
62	EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica, 2019, 104, 947-954.	3.5	33
63	A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis. British Journal of Haematology, 2019, 184, 161-175.	2.5	76
64	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology, 2019, 184, 176-191.	2.5	102
65	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. Blood, 2019, 134, 557-557.	1.4	54
66	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood, 2019, 134, 670-670.	1.4	42
67	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment NaÂ¨ve Myelofibrosis Patients. Blood, 2019, 134, 4164-4164.	1.4	21
68	Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis. Blood, 2019, 134, 671-671.	1.4	36
69	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology, 2018, 4, 652.	7.1	261
70	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
71	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2018, 5, e73-e81.	4.6	211
72	An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. Future Oncology, 2018, 14, 137-150.	2.4	11

#	Article	IF	Citations
73	SOHO State-of-the-Art Update and Next Questions: MPN. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 1-12.	0.4	7
74	Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations. Haematologica, 2018, 103, e234-e236.	3.5	3
75	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica, 2018, 103, 51-60.	3.5	58
76	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. British Journal of Haematology, 2018, 182, 279-284.	2.5	3
77	Hb Baden: a rare high affinity haemoglobin variant and its management. Journal of Clinical Pathology, 2018, 71, 79-80.	2.0	2
78	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. Journal of Clinical Oncology, 2018, 36, 3361-3369.	1.6	54
79	Ruxolitinib for the Treatment of Essential Thrombocythemia. HemaSphere, 2018, 2, e56.	2.7	11
80	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	27.0	442
81	What is preâ€fibrotic myelofibrosis and how should it be managed in 2018?. British Journal of Haematology, 2018, 183, 23-34.	2.5	18
82	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2018, 132, 3032-3032.	1.4	6
83	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	1.4	39
84	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. Blood, 2018, 132, 4289-4289.	1.4	1
85	Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study. Blood, 2018, 132, 1784-1784.	1.4	0
86	Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work. Blood, 2018, 132, 1759-1759.	1.4	0
87	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leukemia Research, 2017, 56, 52-59.	0.8	22
88	Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Review of Hematology, 2017, 10, 617-625.	2.2	29
89	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology,the, 2017, 4, e317-e324.	4.6	243
90	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica, 2017, 102, e238-e240.	3.5	38

#	Article	IF	Citations
91	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematology,the, 2017, 4, e225-e236.	4.6	224
92	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood, 2017, 130, 1889-1897.	1.4	130
93	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Annals of Hematology, 2017, 96, 1653-1665.	1.8	92
94	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology and Oncology, 2017, 10, 156.	17.0	210
95	A discussion of blood cancers and the MPN landmark survey. International Journal of Hematologic Oncology, 2017, 6, 101-104.	1.6	0
96	Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. British Journal of Haematology, 2016, 175, 37-42.	2.5	9
97	Management of polycythaemia vera: a critical review of current data. British Journal of Haematology, 2016, 172, 337-349.	2.5	28
98	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 2016, 101, 821-829.	3.5	140
99	Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica, 2016, 101, e182-e184.	3.5	47
100	Pregnancy outcomes in myeloproliferative neoplasms: <scp>UK</scp> prospective cohort study. British Journal of Haematology, 2016, 175, 31-36.	2.5	65
101	Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. Leukemia and Lymphoma, 2016, 57, 2259-2267.	1.3	16
102	Is there a role for pomalidomide in the treatment of myelofibrosis?. Expert Opinion on Orphan Drugs, 2016, 4, 501-509.	0.8	0
103	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 2016, 101, 926-931.	3.5	118
104	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	1.6	56
105	How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. Current Hematologic Malignancy Reports, 2016, 11, 356-367.	2.3	11
106	JAK inhibitors truly changing the therapeutic paradigm in myelofibrosis. Journal of Medical Economics, 2016, 19, 443-444.	2.1	0
107	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 3117-3117.	1.4	4
108	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. Blood, 2016, 128, 479-479.	1.4	32

#	Article	IF	Citations
109	Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?. British Journal of Haematology, 2015, 170, 323-335.	2.5	12
110	JAK inhibitors and myelofibrosis, Einstein and ruxolitinib. Haematologica, 2015, 100, 409-411.	3.5	10
111	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	3.5	203
112	The use of JAK inhibitors for low-risk myelofibrosis. Expert Review of Hematology, 2015, 8, 551-553.	2.2	19
113	Essential thrombocythaemia. Hematology, 2015, 20, 119-120.	1.5	0
114	Effect of Mutation Order on Myeloproliferative Neoplasms. New England Journal of Medicine, 2015, 372, 601-612.	27.0	467
115	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New England Journal of Medicine, 2015, 372, 426-435.	27.0	720
116	Pacritinib: a new agent for the management of myelofibrosis?. Expert Opinion on Pharmacotherapy, 2015, 16, 2381-2390.	1.8	8
117	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology, 2015, 1, 643.	7.1	362
118	How we diagnose and treat essential thrombocythaemia. British Journal of Haematology, 2015, 171, 306-321.	2.5	20
119	<scp>JAK</scp> inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. British Journal of Haematology, 2015, 171, 60-73.	2.5	73
120	Immunological Consequences of JAK Inhibition: Friend or Foe?. Current Hematologic Malignancy Reports, 2015, 10, 370-379.	2.3	84
121	How We Treat Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S19-S26.	0.4	0
122	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	12.8	145
123	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood, 2015, 126, 825-825.	1.4	24
124	Orphan drugs for myelofibrosis. Expert Opinion on Orphan Drugs, 2014, 2, 391-405.	0.8	2
125	Safety evaluation of ruxolitinib for treating myelofibrosis. Expert Opinion on Drug Safety, 2014, 13, 967-976.	2.4	25
126	Use of <scp>JAK</scp> inhibitors in the management of myelofibrosis: a revision of the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology <scp>G</scp>uidelines for <scp>I</scp>nvestigation and <scp>M</scp>anagement of <scp>M</scp>yelofibrosis 2012. British Journal of Haematology, 2014, 167, 418-420.	2.5	37

#	Article	IF	Citations
127	Update in the myeloproliferative neoplasms. Clinical Medicine, 2014, 14, s66-s70.	1.9	0
128	How many JAK inhibitors in myelofibrosis?. Best Practice and Research in Clinical Haematology, 2014, 27, 187-195.	1.7	5
129	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. British Journal of Haematology, 2014, 167, 421-423.	2.5	40
130	Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: A physician survey. Thrombosis Research, 2014, 134, 251-254.	1.7	28
131	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 2014, 99, 292-298.	3.5	38
132	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 2014, 123, 3803-3810.	1.4	79
133	A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.. Journal of Clinical Oncology, 2014, 32, 7022-7022.	1.6	3
134	A phase II study of vorinostat (<scp>MK</scp>â€0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 2013, 162, 498-508.	2.5	65
135	Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Review of Hematology, 2013, 6, 511-523.	2.2	31
136	Molecular Classification of Myeloproliferative Neoplasmsâ€"Pros and Cons. Current Hematologic Malignancy Reports, 2013, 8, 342-350.	2.3	3
137	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	1.4	286
138	Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leukemia Research, 2013, 37, 162-168.	0.8	29
139	Molecular diagnosis of the myeloproliferative neoplasms: <scp>UK</scp> guidelines for the detection of <scp>JAK</scp>2 <scp>V</scp>617<scp>F</scp> and other relevant mutations. British Journal of Haematology, 2013, 160, 25-34.	2.5	87
140	Healthâ€related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 2013, 162, 229-239.	2.5	75
141	Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?. Journal of Cellular and Molecular Medicine, 2013, 17, 1410-1414.	3.6	5
142	Polycythemia vera: can we do better?. Expert Opinion on Pharmacotherapy, 2013, 14, 687-689.	1.8	1
143	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 2013, 121, 4778-4781.	1.4	219
144	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Therapeutic Advances in Hematology, 2012, 3, 341-354.	2.5	50

#	Article	IF	Citations
145	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology, 2012, 30, 4098-4103.	1.6	344
146	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	27.0	1,543
147	<scp>J</scp>anus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. British Journal of Haematology, 2012, 157, 426-437.	2.5	19
148	Guideline for the diagnosis and management of myelofibrosis. British Journal of Haematology, 2012, 158, 453-471.	2.5	89
149	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. Blood, 2012, 120, 889-889.	1.4	4
150	Myeloproliferative Disorders in Pregnancy. Hematology/Oncology Clinics of North America, 2011, 25, 261-275.	2.2	25
151	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	1.4	280
152	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	1.6	724
153	Aspirin in low-risk essential thrombocythemia, not so simple after all?. Leukemia Research, 2011, 35, 286-289.	0.8	13
154	Management of myelofibrosis â€“ where next?. Expert Opinion on Pharmacotherapy, 2011, 12, 1453-1455.	1.8	2
155	The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. Blood, 2011, 118, 3839-3839.	1.4	4
156	The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. Blood, 2011, 118, 582-582.	1.4	12
157	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	2.5	144
158	Guideline for investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology, 2010, 149, 352-375.	2.5	253
159	Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera. Hematology American Society of Hematology Education Program, 2010, 2010, 129-134.	2.5	19
160	Reply to J. Thiele et al. Journal of Clinical Oncology, 2009, 27, e222-e223.	1.6	7
161	Do we know more about essential thrombocythemia because of JAK2V617F?. Current Hematologic Malignancy Reports, 2009, 4, 25-32.	2.3	1
162	The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research, 2009, 33, 1199-1203.	0.8	203

#	Article	IF	Citations
163	Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood, 2008, 111, 60-70.	1.4	229
164	JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. New England Journal of Medicine, 2007, 356, 459-468.	27.0	1,173
165	Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. British Journal of Haematology, 2007, 138, 821-822.	2.5	99
166	Clinical Significance of MPL Mutations in Essential Thrombocythemia: Analysis of the PT-1 Cohort.. Blood, 2007, 110, 677-677.	1.4	4
167	Impact of Platelet Glycoprotein Polymorphisms upon Clinical Events in Essential Thrombocythaemia Patients Enrolled in the PT1 Trial.. Blood, 2007, 110, 2543-2543.	1.4	0
168	Management of Essential Thrombocythemia: Implications of the Medical Research Council Primary Thrombocythemia 1 Trial. Seminars in Thrombosis and Hemostasis, 2006, 32, 283-288.	2.7	4
169	Myeloproliferative Disorders Are Associated with an Increase in Levels of Prothrombotic and Inflammatory Markers Despite Cytoreductive Therapy.. Blood, 2006, 108, 3625-3625.	1.4	1
170	Natural History of Idiopathic Erythrocytosis â˜’ A Retrospective Case Series Review.. Blood, 2006, 108, 1298-1298.	1.4	3
171	Mechanism of thrombosis in essential thrombocythaemia. Haematologica, 2006, 91, 145b.	3.5	0
172	Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. British Journal of Haematology, 2005, 129, 293-306.	2.5	111
173	Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. British Journal of Haematology, 2005, 130, 174-195.	2.5	314
174	Essential thrombocythaemia: challenges and evidence-based management. British Journal of Haematology, 2005, 130, 153-165.	2.5	79
175	Anagrelide for control of thrombocytosis due to myeloproliferative disorders. Future Oncology, 2005, 1, 609-618.	2.4	4
176	The Presence of the V617F Mutation Is Associated with Higher Haemoglobin, Older Age and an Increased Risk of Thrombosis in Essential Thrombocythemia.. Blood, 2005, 106, 3531-3531.	1.4	1
177	The Use of the PFA-100Â® and Thromboelastograph in Assessing Haemostasis and Drug Efficacy in Essential Thrombocythemia.. Blood, 2005, 106, 4959-4959.	1.4	0
178	The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica, 2005, 90, 1477-83.	3.5	49
179	Clonality in essential thrombocythaemia. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2004, 10, 184-7.	1.2	1
180	Essential thrombocythemia. Hematology/Oncology Clinics of North America, 2003, 17, 1175-1190.	2.2	29

#	Article	IF	Citations
181	Current trends in essential thrombocythaemia. British Journal of Haematology, 2002, 117, 796-808.	2.5	46